HeartBeam, Inc.’s (NASDAQ:BEAT) stock is trading higher on Monday, with a session volume of 193.38 million compared to the average volume of 2.191 million as per data from Benzinga Pro.On Wednesday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for HeartBeam’s 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias.Arrhythmias are irregular heartbeats where the heart beats too fast (tachycardia), too slow (bradycardia), or with an erratic rhythm.The cleara ...